Scientific Opinion on the substantiation of a health claim related to a combination of diosmin, troxerutin and hesperidin and maintenance of normal venous-capillary permeability pursuant to Article 13(5) of Regulation (EC) No 1924/2006

EFSA Journal

Volumn 12, Issue 1, 2014, Pages

[No Author Info available]

Author keywords

diosmin; health claims; hesperidin; troxerutin; venous permeability

Indexed keywords

EID: 85062084533     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2014.3511     Document Type: Article

References (11)

1. Belcaro G, Cesarone MR, Bavera P, Ricci A, Renton S, Leon M, Ippolito E, Dugall M and Acerbi G, 2002. Venoruton1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in chronic venous disease and microangiopathy: an independent prospective, controlled, randomized trial. Journal of Cardiovascular and Pharmacological Therapy. 7, 139–145.
2. Belcaro G, Rosaria Cesarone M, Ledda A, Cacchio M, Ruffini I, Ricci A, Ippolito E, Di Renzo A, Dugall M, Corsi M, Marino Santarelli AR and Grossi MG, 2008. O-(beta-hydroxyethyl)-rutosides systemic and local treatment in chronic venous disease and microangiopathy: an independent prospective comparative study. Angiology. 59 Suppl 1, 7S–13S.
3. Cesarone MR, Belcaro G, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, Di Renzo A, Ruffini I, Gizzi G, Ippolito E, Fano F, Dugall M, Acerbi G, Cornelli U, Hosoi M and Cacchio M, 2006. Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency. Angiology. 57, 131–138.
4. Danielsson G, Jungbeck C, Peterson K and Norgren L, 2002. A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease. European Journal of Vascular and Endovascular Surgery. 23, 73–76.
5. Fortini C, Morelli C and Fiorelli V, 2010. Effetto biologico di una formulazione a base di diosmina, esperidina e troxerutina (Triade®) sulla permeabilità dell'endotelio vasale umano. Il continuum del paziente vascolare. 1, 12–16 (full English translation provided).
6. Jantet G, 2000. RELIEF study: first consolidated European data. Reflux assessment and quality of life improvement with micronized flavonoids. Angiology. 51, 31–37.
7. Jantet G, 2002. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assessment and quality of life improvement with micronized flavonoids. Angiology. 53, 245–256.
8. Kanaze FI, Bounartzi MI, Georgarakis M and Niopas I, 2007. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. European Journal of Clinical Nutrition. 61, 472–477.
9. Kienzler JL, Sallin D, Schifflers MH and Ghika A, 2002. Pharmacokinetics of mono-3′- and mono-4′- O-(β-hydroxyethyl)-rutoside derivates, after single doses of Venoruton powder in healthy volunteers. European Journal of Clinical Pharmacology. 58, 395–402.
10. Spanakis M, Kasmas S and Niopas I, 2009. Simultaneous determination of the flavonoid aglycones diosmetin and hesperetin in human plasma and urine by a validated GC/MS method: in vivo metabolic reduction of diosmetin to hesperetin. Biomedical Chromatography. 23, 124–131.
11. Stuard S, Cesarone MR, Belcaro G, Dugall M, Ledda A, Cacchio M, Ricci A, Ippolito E, Di Renzo A and Grossi MG, 2008. Five-year treatment of chronic venous insufficiency with O-(β- hydroxyethyl)-rutosides: safety aspects. International Journal of Angiology. 17, 143–148.